Abstract
Objective: To examine the trend of provider-verified HPV vaccine initiation (≥1 dose) and completion (≥3 doses) among adolescent girls at the Advisory Committee on Immunization Practices (ACIP) recommended age (11-12 years). Methods: We analyzed National Immunization Survey of Teens 2008-2012 data and examined the trend of provider-verified HPV vaccine initiation and completion among <13 year old girls. Results: Data on age at HPV vaccine initiation and completion were available for 24,466 and 15,972 girls, respectively. The weighted proportion of girls who initiated the vaccine at <13 years of age was 14.1%, 24.1%, 35.9%, 47.7% and 55.9% in 2008, 2009, 2010, 2011 and 2012, respectively (p for trend <.001). The similar trend was also observed for mean age at HPV vaccine initiation and completion (p<. .001). Conclusions: Additional efforts are needed to increase HPV vaccine uptake among adolescent girls as only half of them receive this vaccine at ACIP recommended age.
Original language | English (US) |
---|---|
Pages (from-to) | 585-587 |
Number of pages | 3 |
Journal | Vaccine |
Volume | 33 |
Issue number | 5 |
DOIs | |
State | Published - Jan 29 2015 |
Fingerprint
Keywords
- Adolescent girls
- Age at vaccine completion
- Age at vaccine initiation
- HPV vaccine
- Human papillomavirus (HPV)
ASJC Scopus subject areas
- Immunology and Microbiology(all)
- Infectious Diseases
- Public Health, Environmental and Occupational Health
- veterinary(all)
- Molecular Medicine
Cite this
Age at HPV vaccine initiation and completion among US adolescent girls : Trend from 2008 to 2012. / Rahman, Mahbubur; McGrath, Christine J.; Hirth, Jacqueline; Berenson, Abbey.
In: Vaccine, Vol. 33, No. 5, 29.01.2015, p. 585-587.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Age at HPV vaccine initiation and completion among US adolescent girls
T2 - Trend from 2008 to 2012
AU - Rahman, Mahbubur
AU - McGrath, Christine J.
AU - Hirth, Jacqueline
AU - Berenson, Abbey
PY - 2015/1/29
Y1 - 2015/1/29
N2 - Objective: To examine the trend of provider-verified HPV vaccine initiation (≥1 dose) and completion (≥3 doses) among adolescent girls at the Advisory Committee on Immunization Practices (ACIP) recommended age (11-12 years). Methods: We analyzed National Immunization Survey of Teens 2008-2012 data and examined the trend of provider-verified HPV vaccine initiation and completion among <13 year old girls. Results: Data on age at HPV vaccine initiation and completion were available for 24,466 and 15,972 girls, respectively. The weighted proportion of girls who initiated the vaccine at <13 years of age was 14.1%, 24.1%, 35.9%, 47.7% and 55.9% in 2008, 2009, 2010, 2011 and 2012, respectively (p for trend <.001). The similar trend was also observed for mean age at HPV vaccine initiation and completion (p<. .001). Conclusions: Additional efforts are needed to increase HPV vaccine uptake among adolescent girls as only half of them receive this vaccine at ACIP recommended age.
AB - Objective: To examine the trend of provider-verified HPV vaccine initiation (≥1 dose) and completion (≥3 doses) among adolescent girls at the Advisory Committee on Immunization Practices (ACIP) recommended age (11-12 years). Methods: We analyzed National Immunization Survey of Teens 2008-2012 data and examined the trend of provider-verified HPV vaccine initiation and completion among <13 year old girls. Results: Data on age at HPV vaccine initiation and completion were available for 24,466 and 15,972 girls, respectively. The weighted proportion of girls who initiated the vaccine at <13 years of age was 14.1%, 24.1%, 35.9%, 47.7% and 55.9% in 2008, 2009, 2010, 2011 and 2012, respectively (p for trend <.001). The similar trend was also observed for mean age at HPV vaccine initiation and completion (p<. .001). Conclusions: Additional efforts are needed to increase HPV vaccine uptake among adolescent girls as only half of them receive this vaccine at ACIP recommended age.
KW - Adolescent girls
KW - Age at vaccine completion
KW - Age at vaccine initiation
KW - HPV vaccine
KW - Human papillomavirus (HPV)
UR - http://www.scopus.com/inward/record.url?scp=84921313515&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84921313515&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2014.12.021
DO - 10.1016/j.vaccine.2014.12.021
M3 - Article
C2 - 25529289
AN - SCOPUS:84921313515
VL - 33
SP - 585
EP - 587
JO - Vaccine
JF - Vaccine
SN - 0264-410X
IS - 5
ER -